Abstract
Summary Recommended phase 2 doses for some drugs may differ according to a patient's clinical or genetic characteristics. We develop a new method that determines the individualized optimal dose according to patterns of patient covariates and selects the covariates that are associated with efficacy and toxicity in early phase trials for evaluating multiple patient covariates of interest. To address the difficulty of high dimensional estimation of model parameters with a limited sample size, we propose the use of the Bayesian least absolute shrinkage and selection operator, which is a penalized regression approach. We demonstrate the potential utility of this proposed method through various simulation studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Royal Statistical Society Series C: Applied Statistics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
